Tag Archives: Eli Lilly
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: December 7, 2011
Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
By Ben Comer | Published: June 21, 2011
Can the management style known as Six Sigma help improve the probability of a drug’s commercial success, or do its black-belted acolytes punch holes in the creative process needed for innovative R&D discovery?